Drugs / ALLO-501
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03939026 | May 2019 → Oct 2021 | large B-cell lymphoma | Allogene Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLO-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03939026 ↗ |
| Modality | Cell therapy | “ALLO-501 is an allogeneic CAR T cell therapy targeting CD19” NCT03939026 ↗ |